Enzymes to die for: Exploiting nucleotide metabolizing enzymes for cancer gene therapy

Current Gene Therapy

Volumn 12, Issue 2, 2012, Pages 77-91

  Ardiani, Andressa ^a   Johnson, Adam J ^a   Ruan, Hongmei ^a   Sanchez Bonilla, Marilyn ^a   Serve, Kinta ^a   Black, Margaret E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Bystander effect; Cancer; Enzyme engineering; Mutagenesis; Prodrug; Suicide gene therapy

Indexed keywords

CELL ENZYME; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOSIDE KINASE; ENZYME VARIANT; NUCLEOTIDE METABOLIZING ENZYME; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; SUICIDE ENZYME; THYMIDINE KINASE; UNCLASSIFIED DRUG;

CANCER CELL; CANCER GENE THERAPY; CRYSTAL STRUCTURE; DROSOPHILA MELANOGASTER; ENZYME ENGINEERING; ENZYME SUBSTRATE; ESCHERICHIA COLI; HERPES SIMPLEX VIRUS 1; HUMAN; MUTAGENESIS; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; THERMOSTABILITY;

ADENOSINE DEAMINASE; ENZYMES; GENE THERAPY; HUMANS; NEOPLASMS; NUCLEOSIDE DEAMINASES; NUCLEOTIDASES; NUCLEOTIDES; PRODRUGS; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 84860275842     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312800099571     Document Type: Review

References (118)

1. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. The Lancet 1999; 354(9172): 34-9.
2. Kaldor J, Day N, Pettersson F, et al. Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990; 322(1): 1-6.
3. Curtis R, Jr JB, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326(26): 1745-51.
4. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87(7): 524-31.
5. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999; 340(5): 351-7.
6. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46(10): 5276-81.
7. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187(1): 22-36.
8. Elshami A, Saavedra A, Zhang H, et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3(1): 85-92.
9. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virusthymidine kinase/ganciclovir cancer gene therapy: role of gapjunctional intercellular communication. Cancer Res 2000; 60(15): 3989-99.
10. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki. H. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci U S A 1996; 93(5): 1831-6.
11. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53(21): 5274-83.
12. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A 1994; 91(17): 8302-6.
13. Lawrence TS, Rehemtulla A, Ng EY, Wilson M, Trosko JE, Stetson PL. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. Cancer Res 1998; 58(12): 2588-93.
14. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9(5): 351-60.
15. Carystinos GD, Katabi MM, Laird DW, et al. Cyclic-AMP induction of gap junctional intercellular communication increases bystander effect in suicide gene therapy. Clin Cancer Res 1999; 5(1): 61-8.
16. Tanaka T, Yamasaki H, Mesnil M. Induction of a bystander effect in HeLa cells by using a bigenic vector carrying viral thymidine kinase and connexin32 genes. Mol Carcinog 2001; 30(3): 176-80.
17. Estin D, Li M, Spray D, Wu JK. Connexins are expressed in primary brain tumors and enhance the bystander effect in gene therapy. Neurosurgery 1999; 44(2): 361-8.
18. Kuriyama S, Kikukawa M, Masui K, et al. Cytosine deaminase/5-fluorocytosine gene therapy can induce efficient anti-tumor effects and protective immunity in immunocompetent mice but not in athymic nude mice. Int J Cancer 1999; 81(4): 592-7.
19. Kuriyama S, Kikukawa M, Masui K, et al. Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo. Int J Cancer 1999; 83(3): 374-80.
20. Nishiyama T, Kawamura Y, Kawamoto K, et al. Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. Cancer Res 1985; 45(4): 1753-61.
21. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosineinduced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154(10): 5302-12.
22. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a nonimmunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71(2): 267-74.
23. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 1993; 90(15): 7024-8.
24. Kim YG, Bi W, Feliciano ES, Drake RR, Stambrook PJ. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene. Cancer Gene Ther 2000; 7(2): 240-6.
25. Davies LC, Friedlos F, Hedley D, et al. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. J Med Chem 2005; 48(16): 5321-8.
26. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res 2000; 60(6): 1631-6.
27. Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res 2006; 66(6): 3230-7.
28. Willmon CL, Krabbenhoft E, Black ME. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther 2006; 13(17): 1309-12.
29. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60(14): 3813-22.
30. Tiraby M, Cazaux C, Baron M, Drocourt D, Reynes J, Tiraby G. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998; 167(1): 41-9.
31. Fuchita M, Ardiani A, Zhao L, Serve K, Stoddard BL, Black ME. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res 2009; 69(11): 4791-9.
32. Stolworthy TS, Korkegian AM, Willmon CL, et al. Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J Mol Biol 2008; 377(3): 854-69.
33. Black ME, Kokoris MS, Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 2001; 61(7): 3022-6.
34. Kaliberov SA, Market JM, Gillespie GY, et al. Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma. Gene Ther 2007; 14(14): 1111-9.
35. Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci 2002; 11(9): 2267-72.
36. Dachs GU, Tupper J, Tozer GM. From bench to bedside for genedirected enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16(4): 349-59.
37. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong J-Y, et al. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol 2005; 1(1): 115-23.
38. Niculescu-Duvaz I, Springer C. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30(1): 71-88.
39. Lutz S, Patrick WM. Novel methods for directed evolution of enzymes: quality, not quantity. Curr Opin Biotechnol 2004; 15(4): 291-7.
40. Neylon C. Chemical and biochemical strategies for the randomization of protein encoding DNA sequences: library construction methods for directed evolution. Nucl Acids Res 2004; 32(4): 1448-59.
41. Bloom JD, Meyer MM, Meinhold P, Otey CR, MacMillan D, Arnold FH. Evolving strategies for enzyme engineering. Curr Opin Struct Biol 2005; 15(4): 447-52.
42. Devanathan S, Willmon CL, Mahan SD, Black ME. Engineering enzymes for improved cancer gene therapy. Res Adv in Cancer 2002; 2: 315-26.
43. Encell LP, Landis DM, Loeb LA. Improving enzymes for cancer gene therapy. Nat Biotechnol 1999; 17(2): 143-7.
44. Mahan SD, Ireton GC, Stoddard BL, Black ME. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference. Biochemistry 2004; 43(28): 8957-64.
45. Field AK, Davies ME, DeWitt C, et al. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc Natl Acad Sci U S A1983; 80(13): 4139-43.
46. Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KF. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem 1983; 258(20): 12460-4.
47. Ashton W, Karkas J, Field A, Tolman R. Activation by thymidine kinase and potent antiherpetic activity of 2'-nor-2'-deoxyguanosine (2'NDG). Biochem Biophys Res Commun 1982; 108(4): 1716-21.
48. Candolfi M, Kroeger K, Muhammad A, et al. Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther 2009; 9(5): 409-21.
49. Määttä A, Samaranayake H, Pikkarainen J, Wirth T, Ylä-Herttuala S. Adenovirus mediated herpes simplex virus-thymidine kinase/ganciclovir gene therapy for resectable malignant glioma. Curr Gene Ther 2009; 9(5): 356-67.
50. Singhal S, Kaiser L. Cancer chemotherapy using suicide genes. Surg Oncol Clin N Am 1998; 7(3): 505-36.
51. Black M. Enzyme and pathway engineering for suicide gene therapy. Genet Eng (N Y) 2001; 23: 113-27.
52. Black M, Newcomb T, Wilson H, Loeb L. Creation of drugspecific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A 1996; 93(8): 3525-9.
53. Mercer KE, Ahn CE, Coke A, Compadre CM, Drake RR. Mutation of herpesvirus thymidine kinase to generate ganciclovir-specific kinases for use in cancer gene therapies. Protein Eng 2002; 15(11): 903-11.
54. Likar Y, Dobrenkov K, Olszewska M, et al. A new acycloguanosine-specific supermutant of herpes simplex virus type 1 thymidine kinase suitable for PET imaging and suicide gene therapy for potential use in patients treated with pyrimidine-based cytotoxic drugs. J Nucl Med 2008; 49(5): 713-20.
55. Black M, Loeb L. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro. Biochemistry 1993; 32: 11618-26.
56. Kokoris M, Sabo P, Adman E, Black ME. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther 1999; 6(8): 1415-26.
57. Qiao J, Black ME, Caruso M. Enhanced ganciclovir killing and bystander effect of human tumor cells transduced with a retroviral vector carrying a herpes simplex virus thymidine kinase gene mutant. Hum Gene Ther 2000; 11(11): 1569-76.
58. Pantuck AJ, Matherly J, Zisman A, et al. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther 2002; 13(7): 777-89.
59. Wiewrodt R, Amin K, Kiefer M, et al. Adenovirus-mediated gene transfer of enhanced herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 2003; 10(5): 353-64.
60. Ardiani A, Sanchez-Bonilla M, Black M. Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther 2009; 17(2): 86-96.
61. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 2000; 97(6): 2785-90.
62. Pantuck AJ, Berger F, Zisman A, et al. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol 2002; 168(3): 1193-8.
63. Yang H, Berger F, Tran C, Gambhir SS, Sawyers CL. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate 2003; 55(1): 39-47.
64. Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther 2005; 12(3): 329-39.
65. Jacobs AH, Rueger MA, Winkeler A, Li H, Vollmar S, Waerzeggers Y, et al. Imaging-guided gene therapy of experimental gliomas. Cancer Res 2007; 67(4): 1706-15.
66. Balzarini J, Liekens S, Solaroli N, El Omari K, Stammers DK, Karlsson A. Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation. J Biol Chem 2006; 281(28): 19273-9.
67. Preuß E, Muik A, Weber K, Otte J, von Laer D, Fehse B. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J Mol Med 2011; 89(11): 1113-24.
68. Hinds TA, Compadre C, Hurlburt BK, Drake RR. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities. Biochemistry 2000; 39(14): 4105-11.
69. Degreve B, Esnouf R, De Clercq E, Balzarini J. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine-167 to tyrosine. Mol Pharmacol 2000; 58(6): 1326-32.
70. Balzarini J, Liekens S, Esnouf R, De Clercq E. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase. Biochemistry 2002; 41(20): 6517-24.
71. Drake RR, Wilbert TN, Hinds TA, Gilbert KM. Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase. J Biol Chem 1999; 274(52): 37186-92.
72. Degreve B, Esnouf R, De Clercq E, Balzarini J. Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase. Mol Pharmacol 2001; 59(2): 285-93.
73. Ireton GC, McDermott G, Black ME, Stoddard BL. The structure of Escherichia coli cytosine deaminase. J Mol Biol 2002; 315(4): 687-97.
74. Mahan SD, Ireton GC, Knoeber C, Stoddard BL, Black ME. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy. Protein Eng Des Sel 2004; 17(8): 625-33.
75. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000; 46(2): 171-9.
76. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993; 43(3): 380-7.
77. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3(5): 330-8.
78. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000; 60(23): 6649-55.
79. Kaliberova L, Manna D, Krendelchtchikova V, Black M, Buchsbaum D, Kaliberov S. Molecular chemotherapy of pancreatric cancer using novel mutant bacterial cytosine deaminase gene. Mol Cancer Ther 2008; 7(9): 2845-54.
80. Deng L-Y, Wang J-P, Gui Z-F, Shen L-Z. Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. World J Gastoenterol 2011; 17(24): 2958-64.
81. Korkegian A, Black ME, Baker D, Stoddard BL. Computational thermostabilization of an enzyme. Science 2005; 308(5723): 857-60.
82. Munch-Petersen B, Piskur J, Sondergaard L. Four deoxynucleoside kinase activities from Drosophila melanogaster are contained within a single monomeric enzyme, a new multifunctional deoxynucleoside kinase. J Biol Chem 1998; 273(7): 3926-31.
83. Zheng X, Johansson M, Karlsson A. Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 2000; 275(50): 39125-9.
84. Knecht W, Munch-Petersen B, Piskur J. Identification of residues involved in the specificity and regulation of the highly efficient multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster. J Mol Biol 2000; 301(4): 827-37.
85. Knecht W, Rozpedowska E, Le Breton C, Willer M, Gojkovic Z, Sandrini MPB, et al. Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs. Gene Ther 2007; 14(17): 1278-86.
86. Welin M, Skovgaard T, Knecht W, Zhu C, Berenstein D, Munch-Petersen B, et al. Structural basis for the changed substrate specificity of Drosophila melanogaster deoxyribonucleoside kinase mutant N64D. FEBS J 2005; 272(14): 3733-42.
87. Knecht W, Sandrini M, Johansson K, Eklund H, Munch-Petersen B, Piskur J. A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines. EMBO J 2002; 21(7):1873-80.
88. Munch-Petersen B, Knecht W, Lenz C, Sondergaard L, Piskur J. Functional expression of a multisubstrate deoxyribonucleoside kinase from Drosophila melanogaster and its C-terminal deletion mutants. J Biol Chem 2000; 275(9): 6673-9.
89. Solaroli N, Johansson M, Balzarini J, Karlsson A. Enhanced toxicity of purine nucleoside analogs in cells expressing Drosophila melanogaster nucleoside kinase mutants. Gene Ther 2007; 14(1): 89-62.
90. Gerth ML, Lutz S. Non-homologous recombination of deoxyribonucleoside kinases from human and Drosophila melanogaster yields human-like enzymes with novel activities. J Mol Biol 2007; 370(4): 742-51.
91. Liu L, Li Y, Liotta D, Lutz S. Directed evolution of an orthogonal nucleoside analog kinase via fluorescence-activated cell sorting. Nucl Acids Res 2009; 37(13): 4472-81.
92. Lutz S, Liu L, Liu Y. Engineering kinases to phosphorylate nucleoside analogs for antiviral and cancer therapy. Chimia (Aarau) 2009; 63(11): 737-44.
93. Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 2003; 10(7): 513-9.
94. Stegmann AP, Honders WH, Willemze R, Ruiz van Haperen VW, Landegent JE. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC-and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity. Blood 1995; 85(5): 1188-94.
95. Hapke DM, Stegmann AP, Mitchell BS. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996; 56(10): 2343-7.
96. Manome Y, Wen P, Dong Y, Tanaka T, Mitchell BS, Kufe D, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2(5): 567-73.
97. Réjiba S, Bigand, C., Parmentier, C., Hajri, A. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009; 11(7): 637-50.
98. Cottin S, Ghani K, de Campos-Lima P, Caruso M. Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy. Mol Cancer 2010; 9(1): 141.
99. Hazra S, Sabini E, Ort S, Konrad M, Lavie A. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry 2009; 48(6): 1256-63.
100. Iyidogan P, Lutz S. Systematic exploration of active site mutations on human deoxycytidine kinase substrate specificity. Biochemistry 2008; 47(16): 4711-20.
101. Smal C, Vertommen D, Bertrand L, et al. Identification of in vivo phosphorylation sites on human deoxycytidine kinase: role of Ser-74 in the control of enzyme activity. J Biol Chem 2006; 281(8): 4887-93.
102. McSorley T, Ort S, Hazra S, Lavie A, Konrad M. Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues. FEBS Lett 2008; 582(5): 720-4.
103. Kikuchi E, Menendez S, Ozu C, et al. Delivery of replicationcompetent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Cancer Gene Ther 2007; 14(3): 279-86.
104. Sophie D, Séverine W, Marc A, Amor H. Transcriptional tumorselective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med 2005; 7(5): 672-80.
105. Sorscher E, Peng S, Bebok Z, Allan P, Bennett L, Parker W. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1(4): 233-8.
106. Tai C-K, Wang W, Lai Y-H, et al. Enhanced efficiency of prodrug activation therapy by tumor-selectively replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene. Cancer Gene Ther 2010; 17(9): 614-23.
107. Parker WB, Allan PW, Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998; 55(10): 1673-81.
108. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res 1995; 55(15): 3339-45.
109. Gadi V, Alexander S, Kudlow J, Allan P, Parker W, Sorscher E. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 2000; 7(20): 1738-43.
110. Deharvengt S, Wack S, Uhring M, Aprahamian M, Hajri A. Suicide gene/prodrug therapy for pancreatic adenocarcinoma by E. coli purine nucleoside phosphorylase and 6-methylpurine 2'-deoxyriboside. Pancreas 2004; 28(2): e54-64.
111. Bharara S, Sorscher EJ, Gillespie GY, et al. Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy. Hum Gene Ther 2005; 16(3): 339-47.
112. Rosetta M-W, Allison D, Dale JV, et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004; 6(1): 43-54.
113. Lubin M, Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. PLoS One 2009; 4(5): e5735.
114. Bennett EM, Anand R, Allan PW, et al. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem Biol 2003; 10(12): 1173-81.
115. Secrist J, Parker W, Allan P, et al. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 1999; 18(4-5): 745-57.
116. Parker W, Allan P, Ealick S, et al. Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucleosides Nucleotides Nucleic Acids 2005; 24(5-7): 387-92.
117. Silamkoti A, Allan P, Hassan A, et al. Synthesis and biological activity of 2-fluoro adenine and 6-methyl purine nucleoside analogs as prodrugs for suicide gene therapy of cancer. Nucleosides Nucleotides Nucleic Acids 2005; 24(5-7): 881-5.
118. Gopinath P, Ghosh S. Apoptotic induction with bifunctional E. coli suicide gene therapy is synergized by curcumin treatment in vitro. Mol Biotechnol 2008; 39: 39-48.